Objective:To explore the etiology and drug resistance of the ICU ventilator-associated pneumonia.Methods: One hundred cases of patients with ventilator-associated pneumonia received in our ICU room were selected; the pathologic examination results were retrospectively analyzed.Results: One hundred and thirty five bacteria were isolated from 100 cases of patients with ventilator-associated pneumonia, including 95 cases of Gram-negative bacilli(70.5%), 34 cases of Gram-positive cocci(25.1%) and 6 cases of fungi(4.4%); The resistance rates of Pseudomonas aeruginosa and Klebsiella pneumoniae for cefazolin, gentamicin, levofloxacin, and trimethoprim-sulfamethoxazole were high; The resistance rate of Staphylococcus aureus for ceftazidime, ceftriaxone, cefepime, cefazolin, gentamicin, amikacin, ciprofloxacin, levofloxacin, cefoperazone/sulbactam and piperacillin were high.Conclusion: ICU ventilator-associated pneumonia pathogen was mainly Gram-negative bacteria, and showed multidrug resistance, imipenem and cefoperazone/sulbactam for most pathogens had better efficacy and worthy of clinical application.

This article summarized some in vitro models of drug absorption,whose shortcomings and virtues were compared in order to be convenient for researchers to know and select optimal model.

Objective:To study the expression of p73? and its clinical significance in breast carcinoma.Methods:The expression of p73? was detected by immunohistochemistry in 41 breast carcinoma tissues,13 benign breast tumor tissues and 8 normal breast tissues.Results:The positive expression of p73? was found in 20/41(48.8%) of breast carcinoma tissues,1/13(7.7%)of benign breast tumor tissues,0/8(0)of normal breast tissues.The positive expression rate of p73? in breast carcinoma tissues was significantly higher than that in benign breast tumor tissues or normal breast tissues(P

Objective:To find a better way to protect the security and interests of vulnerable groups by exploring the problem of protecting the vulnerable groups in drug clinical trial from the perspectives of ethics committees,organization and researchers.Methods:According to the relevant literature and the actual situation of the hospital,this paper analyzed the security issues of vulnerable groups comprehensively.Results:Only the ethics committees,organization and researchers work together,can it protect the security and interests of vulnerable groups to the greatest extents.Conclusion:Further research on the security of vulnerable groups not only promotes the development of human health,but also plays a decisive role in improving the protection of subjects in drug clinical trial.

0.05).CONCLUSION A similar MMN exists in guinea pigs and human.MMN has a process of development,differentiation and maturation with aging. Guinea pigs can serve as the candidate animal for MMN research.Comparing with ABR,MMN is more sensitive to evaluate the central auditory function.

Objective To evaluate 18F-FDG PET/CT imaging in primary adrenal lymphoma (PAL). Methods Three male patients with clinically diagnosed PAL, aged 59 to 77 years old, were examined by18F-FDG PET/CT before histopathologic examination. The SUVmax ratio of tumor to liver (T/L)was calculated on 18F-FDG PET images. All patients underwent R-CHOP ( rituximab-cyclophosphamide,doxorubicin, vincristine, and prednisone) chemotherapy regimens. One patient had serial follow-up 18F-FDG PET/CT post therapy. Results The final diagnosis of all 3 cases was bilateral diffuse large B-cell lymphoma. The pathologic results of bone marrow biopsy were negative. Case 1 was in disease remission based on four times of follow-up 18F-FDG PET/CT. The patient's clinical follow-up was also negative and he was currently alive for more than 19 months. Case 2 was of late stage and suffered from adrenal insufficiency. He died 6 months after the diagnosis. Case 3 (the eldest patient) was treated with partial excision followed by the chemotherapy. He died of lung infection 12 months after treatment. Conclusion 18 F-FDG PET/CT may be of important value for maximizing patient management and survival for patients with PAL, a rare and highly malignant disease.

@@

Objective To investigate the changes of plasma vascular endothelial growth factor( VEGF) of patients of advanced primary liver cancer before and after interventional treatment and its clinical Significance. Methods Forty-six patients with advanced primary liver cancer were performed the hepatic arterial chemoembolization and served as observation group. Sixty healthy people were served as control group and measured their level of serum VEGF. The level of serum VEGF of patients in observation group before treatment and intervention 1 month were measured. Results Before interventional treatment,the serum VEGF level of observation group were(510. 0 ± 310. 0)ng/L,significantly higher than that of control group((27. 0 ± 23. 0) ng/L,P﹤0. 001). After interventional treatment,he serum VEGF level decreased to(316. 4 ± 240. 7)ng/L and the difference was statistically significant( P=0. 036 ). After one month interventional treatment,4 cases were complete remission(8. 70%),34 cases were partial remission(73. 91%),6 cases were in stable(13. 04%),and 2 cases were progress( 4. 35%),and the total effective rate were 82. 61%( 38/46 ). The 38 cases who were complete remission and partial remission were been served as effective group,the other 8 cases were served as invalid group. The serum VEGF level in effective group were( 260. 6 ± 70. 5 )ng/L,lower than that in invalid group(( 346. 7 ± 61. 3 )ng/L,P = 0. 046 ). Conclusion Hepatic arterial chemoembolization treatment on primary liver cancer curative effect is a better approach. VEGF involves in the development of primary liver cancer,and the high serum VEGF level with poor prognosis can be the reference of efficacy.

Mantle cell lymphoma (MCL), is a disease with high heterogeneity, which is insensitivity to the chemotherapy and presents poor prognosis. Appearance of the Bruton tyrosine kinase (BTK) targeted inhibitors, such as ibrutinib, provides novel treatment strategy for MCL. This review focused on the latest achievements of BTK inhibitors in MCL treatment.